checkAd
    Startseite > Aktien > Atara Biotherapeutics > Nachrichten
    Atara Biotherapeutics Aktie
    0,4853
     
    EUR
    -0,59 %
    -0,0029 EUR
    Letzter Kurs 14:19:36 Tradegate
    0,4855
     
    EUR
    5.150 STK
    Geldkurs 14:49:22
    0,5098
     
    EUR
    4.910 STK
    Briefkurs 14:49:22
    ISIN: US0465131078 · WKN: A1166A · SYM: AT2 · USA

    Neueste Nachrichten

    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    07.06.24 · Business Wire (engl.) · Atara Biotherapeutics
    Atara Biotherapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
    05.06.24 · Business Wire (engl.) · Atara Biotherapeutics
    Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
    29.05.24 · Business Wire (engl.) · Atara Biotherapeutics
    Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
    20.05.24 · Business Wire (engl.) · Atara Biotherapeutics
    Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
    09.05.24 · Business Wire (engl.) · Atara Biotherapeutics
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    03.05.24 · Business Wire (engl.) · Atara Biotherapeutics
    Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    05.04.24 · Business Wire (engl.) · Atara Biotherapeutics
    Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
    28.03.24 · Business Wire (engl.) · Atara Biotherapeutics
    Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
    29.02.24 · Business Wire (engl.) · Atara Biotherapeutics
    Atara Biotherapeutics to Participate in Cell Therapy Panel Discussion at the Cowen 44th Annual Health Care Conference
    28.02.24 · Business Wire (engl.) · Atara Biotherapeutics
    Atara Biotherapeutics Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis
    14.02.24 · Business Wire (engl.) · Atara Biotherapeutics
    Atara: Nächster Verdoppler für NBC-Mitglieder!
    07.02.24 · Sharedeals · Atara Biotherapeutics